Merck’s NDA for Cordaptive (ER niacin/laropiprant), formerly known as MK-0524A, has been accepted for review by the FDA. Cordaptive is an investigational drug containing Merck’s extended-release niacin and laropiprant, a flushing pathway inhibitor designed to reduce flushing associated with niacin treatment. The application supports the use of Cordaptive, either alone or with a statin, as adjunctive therapy to diet for the treatment of elevated LDL cholesterol (LDL-C or “ba...